首页> 外文期刊>Pharmacological reviews >International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.
【24h】

International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

机译:国际基础和临床药理学联盟。 LXXIII。甲酰基肽受体(FPR)家族的命名法。

获取原文
获取原文并翻译 | 示例
           

摘要

Formyl peptide receptors (FPRs) are a small group of seven-transmembrane domain, G protein-coupled receptors that are expressed mainly by mammalian phagocytic leukocytes and are known to be important in host defense and inflammation. The three human FPRs (FPR1, FPR2/ALX, and FPR3) share significant sequence homology and are encoded by clustered genes. Collectively, these receptors bind an extraordinarily numerous and structurally diverse group of agonistic ligands, including N-formyl and nonformyl peptides of different composition, that chemoattract and activate phagocytes. N-formyl peptides, which are encoded in nature only by bacterial and mitochondrial genes and result from obligatory initiation of bacterial and mitochondrial protein synthesis with N-formylmethionine, is the only ligand class common to all three human receptors. Surprisingly, the endogenous anti-inflammatory peptide annexin 1 and its N-terminal fragments also bind human FPR1 and FPR2/ALX, and the anti-inflammatory eicosanoid lipoxin A4 is an agonist at FPR2/ALX. In comparison, fewer agonists have been identified for FPR3, the third member in this receptor family. Structural and functional studies of the FPRs have produced important information for understanding the general pharmacological principles governing all leukocyte chemoattractant receptors. This article aims to provide an overview of the discovery and pharmacological characterization of FPRs, to introduce an International Union of Basic and Clinical Pharmacology (IUPHAR)-recommended nomenclature, and to discuss unmet challenges, including the mechanisms used by these receptors to bind diverse ligands and mediate different biological functions.
机译:甲酰基肽受体(FPRs)是一小组七跨膜结构域,G蛋白偶联受体,主要由哺乳动物吞噬白细胞表达,并且已知在宿主防御和炎症中很重要。三个人类FPR(FPR1,FPR2 / ALX和FPR3)具有明显的序列同源性,并由簇状基因编码。这些受体共同地结合了众多的和结构上多样化的激动剂配体,包括化学组成并激活吞噬细胞的不同组成的N-甲酰基和非甲酰基肽。 N-甲酰肽是自然界中仅由细菌和线粒体基因编码的肽,是由N-甲酰甲硫氨酸强制性合成细菌和线粒体蛋白质而产生的,是所有这三种人类受体共有的唯一配体类别。令人惊讶地,内源性抗炎肽膜联蛋白1及其N末端片段也结合人FPR1和FPR2 / ALX,并且抗炎类花生酸脂蛋白A4是FPR2 / ALX的激动剂。相比之下,已针对FPR3(该受体家族的第三成员)鉴定出了较少的激动剂。 FPRs的结构和功能研究为理解控制所有白细胞趋化因子受体的一般药理原理提供了重要信息。本文旨在概述FPR的发现和药理特性,介绍国际基础和临床药理学联盟(IUPHAR)推荐的命名法,并讨论未满足的挑战,包括这些受体结合不同配体所使用的机制并介导不同的生物学功能

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号